Galera Therapeutics (GRTX) Competitors $0.02 +0.00 (+10.26%) As of 09/12/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. APVO, TCRT, OGEN, ORGS, REVB, XBIO, ADTX, CMND, JAGX, and INMShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Aptevo Therapeutics (APVO), Alaunos Therapeutics (TCRT), Oragenics (OGEN), Orgenesis (ORGS), Revelation Biosciences (REVB), Xenetic Biosciences (XBIO), Aditxt (ADTX), Clearmind Medicine (CMND), Jaguar Animal Health (JAGX), and InMed Pharmaceuticals (INM). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Aptevo Therapeutics Alaunos Therapeutics Oragenics Orgenesis Revelation Biosciences Xenetic Biosciences Aditxt Clearmind Medicine Jaguar Animal Health InMed Pharmaceuticals Galera Therapeutics (NASDAQ:GRTX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings. Does the media favor GRTX or APVO? In the previous week, Aptevo Therapeutics had 4 more articles in the media than Galera Therapeutics. MarketBeat recorded 4 mentions for Aptevo Therapeutics and 0 mentions for Galera Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.72 beat Galera Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Galera Therapeutics Neutral Aptevo Therapeutics Positive Which has higher earnings & valuation, GRTX or APVO? Aptevo Therapeutics has higher revenue and earnings than Galera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.19-0.11Aptevo Therapeutics$3.11M1.56-$24.13MN/AN/A Do institutionals and insiders hold more shares of GRTX or APVO? 50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is GRTX or APVO more profitable? Galera Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Aptevo Therapeutics N/A -675.52%-175.68% Which has more risk & volatility, GRTX or APVO? Galera Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.78, suggesting that its share price is 478% more volatile than the S&P 500. Do analysts prefer GRTX or APVO? Aptevo Therapeutics has a consensus target price of $219,040.00, suggesting a potential upside of 14,900,580.27%. Given Aptevo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aptevo Therapeutics is more favorable than Galera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAptevo Therapeutics beats Galera Therapeutics on 8 of the 12 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.62M$862.26M$5.78B$10.18BDividend YieldN/A4.84%5.73%4.60%P/E Ratio-0.061.1775.5726.02Price / SalesN/A127.38461.9291.11Price / CashN/A19.5625.8129.91Price / Book-0.016.6812.526.25Net Income-$59.08M-$4.13M$3.29B$270.76M7 Day PerformanceN/A8.83%0.78%2.54%1 Month PerformanceN/A8.28%4.56%5.73%1 Year PerformanceN/A23.90%66.82%25.85% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.02+10.3%N/A-68.4%$1.62MN/A-0.0630Gap UpAPVOAptevo Therapeutics2.4029 of 5 stars$1.53+3.4%$219,040.00+14,316,239.9%-100.0%$4.87M$3.11M0.0050News CoverageShort Interest ↑Gap UpTCRTAlaunos Therapeutics0.3353 of 5 stars$2.30+5.0%N/A-0.9%$4.83M$10K-0.9340Positive NewsGap UpOGENOragenics0.1029 of 5 stars$1.17-0.4%N/A-92.4%$4.81MN/A-0.165Short Interest ↑ORGSOrgenesisN/A$1.00+525.0%N/AN/A$4.80M$662K0.00150Gap UpREVBRevelation Biosciences0.8601 of 5 stars$2.33-17.4%N/A-95.6%$4.79MN/A-0.0310Gap DownHigh Trading VolumeXBIOXenetic Biosciences1.3121 of 5 stars$3.05-0.2%N/A-9.8%$4.70M$2.50M-1.524Gap DownADTXAditxtN/A$1.07+16.1%N/A-100.0%$4.59M$12.05K0.0060CMNDClearmind Medicine1.4345 of 5 stars$1.03+2.2%N/A-23.9%$4.31MN/A-0.94N/AEarnings ReportShort Interest ↓Gap UpJAGXJaguar Animal Health1.6503 of 5 stars$1.93-2.5%$60.00+3,008.8%-92.9%$4.31M$11.81M0.0050Positive NewsShort Interest ↑Gap UpINMInMed Pharmaceuticals1.2653 of 5 stars$2.25+4.7%N/A-59.1%$4.30M$4.60M-0.1910News CoveragePositive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies APVO Competitors TCRT Competitors OGEN Competitors ORGS Competitors REVB Competitors XBIO Competitors ADTX Competitors CMND Competitors JAGX Competitors INM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
